Executive Summary
Maximus Federal Services, Inc. holds a $104.1M CMS firm fixed price contract for Medicare Part C QIC services, with $86.6M outlayed and $17.5M remaining through April 2026, signaling strong revenue visibility. This full-and-open award underscores sustained federal demand for administrative consulting in healthcare. Bullish for Maximus amid execution risks from fixed pricing.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Federal Professional Services Contracts digest from February 28, 2026.
Investment Signals (1)
- Maximus Secures $104M CMS Revenue Stream (HIGH)▲
$104.1M obligation with $86.6M outlayed provides steady cash flows through April 2026 under full-and-open competition.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Firm fixed price structure may compress margins if costs exceed obligations during remaining performance.
Opportunities (1)
- ◆
$17.5M unoutlayed obligation plus extension/follow-on potential beyond April 2026 end date.
Sector Themes (1)
- ◆
Single large award highlights federal reliance on NAICS 541611 consulting for Part C QIC services.
Watch List (1)
- 👁
{"entity"=>"Maximus Federal Services, Inc.", "reason"=>"$104M CMS contract with $17.5M remaining and 2026 expiration signals renewal potential.", "trigger"=>"New awards, extensions, or outlay acceleration post-March 2026"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Federal Professional Services Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals